Gene and sugar response study with oral semaglutide
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how your genes affect your body's response to a diabetes medication called semaglutide. It may help people with slightly high blood sugar (pre-diabetes) understand why some respond better than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You are male, or female and not pregnant
- Your fasting blood sugar is between 100 and 125 mg/dL based on past lab results
- You are not currently taking medication for diabetes
- You have not had weight loss surgery, gallbladder disease, pancreatitis, or certain digestive issues
- You do not have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a weight-loss medication affects people with obesity who may have a specific gene difference (caveolin-1). It aims to understand why some people respond differently to GLP-1 treatments like semaglutide.
This study looks at how genetics may affect your body’s early response to oral semaglutide, a weight-related diabetes medicine. You may be considered if you are overweight (or overweight with prediabetes) and can safely take part in the research.
This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.
This study looks at how your genes may change how well a GLP-1–type medicine works to improve prediabetes. It focuses on adults at higher risk of developing diabetes, especially people of Mexican-American background.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
Hear when a new Genetic Predisposition trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.